MissionIR Small-Cap Investor Blog: July 2014

Wednesday, July 30, 2014

Continental Stock Transfer & Trust – A Proven Agent for Small and Mid-Sized Clients

Continental Stock Transfer and Trust is a recognized stock transfer agent employing its long history in the industry to better serve its customers. The company was founded in 1963 and, in the decades since, has not wavered from pursuing its vision to support small and medium-sized emerging and growth companies with exclusively tailored business solutions and exceptional client awareness, accessibility, and responsiveness. Right from the start, Continental has been an independent, privately-held, family-owned corporation committed to partnering with clients for the long term and it has no intention of changing.

The company holds a firm belief that an organization’s true strength lies in its people and, for five decades, it has gathered some of the industry’s most experienced experts to ask the right questions, provide the right answers and deliver the right type of support to its clients and their shareholders. The company’s foundation and top-level management and staff allow it to swiftly and deftly react to client and shareholder requests. They also make it possible for Continental to design and flawlessly execute its services according to what is best for each client. This way of doing business has held the company in good stead and helped it carve out a significant presence in the industry. It is the basis of Continental’s pledge to never settle for the way things are usually done and inspires the company’s motto: Power of stability. Spirit of agility.

Continental is devoted to companies with 50,000 or fewer shareholders and presently backs more than 1,100 public issues, i.e. 2.5 million shareholders of record across the nation. Even though it is the fourth largest agent in the United States, the company serves its clients and their shareholders in ways other large transfer agents cannot; it offers personal attention from senior staff, flexible offerings, innovative technology, exceptional execution and unmatched value.

The company strives to make its clients the center of attention. It is exceedingly proud of its history but even more so of the fact that it satisfies its clients time and again, and yearly industry surveys repeatedly confirm that it offers the best value among major agents.

In keeping with its responsibility to support client businesses, Continental endeavors to stay ahead of developing rules, regulations and industry trends. The company’s long-term experience makes this second nature and it is always eager to share its expertise and advice on noteworthy events.

For more information, visit www.continentalstock.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Resonant Inc. (RESN) Set to Disrupt RF Front-End Market

Resonant, based in Santa Barbara, California, is set to overturn one of the key elements of RF (Radio Frequency) technology application. RF filters, used as a front-end in mobile devices to select desired RF signals while rejecting unwanted signals, are currently based upon technology that has changed little over the past century. The current approach to RF transmit filter development is to incrementally improve a fundamental design patented in 1931. Resonant is using a new technology, called Infinite Synthesized Networks (ISN), as a basis for superior RF filter design, addressing previously intractable problems in RF filters.

The recent rapid growth in wireless data, requiring an increase in the number of wireless channels or frequency bands, calls for a new approach to filter design. ISN is a process that starts from the ground up, unconstrained by conventional design limitations, and it is expected to disrupt the RF front-end market by offering the following advantages:

• Significant Cost Reductions

• Reduced Size

• Fewer Components

• Superior Performance

Resonant’s immediate focus is the design of single-band and tunable filters for the RF front-end, designs that have the greatest near-term potential for commercialization of this new technology. The goal of a tunable filter is to replace multiple filters with a single tunable filter, saving both cost and valuable space. Licensing the designs is the most direct and effective means of getting the technology to market, targeting customers that produce part or all of the RF front-end and who sell directly to cell phone and mobile device manufacturers. The company has key advantages representing barriers to potential competitors:

• Large and growing patent portfolio

• Suite of proprietary software design tools

• Highly experienced design team

• Multi-year technology lead

Resonant is a client of MZ Group, the largest investor relations group in the world.

For more information, visit www.Resonant.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Qihoo 360 Technology (QIHU) Leverages User Base of 400 Million

Qihoo 360 Technology, a leading Beijing-based Internet and mobile security products and services company, provides high-quality free security services for over 400 million Chinese Internet users. The company offers cloud-based security technologies, along with a variety of storage, browser, and other products.

• Core Security – The company has two core Internet security products: 360 Safe Guard and 360 Anti-Virus. 360 Safe Guard, their flagship Internet security software, is a one-stop solution for Internet security and system optimization. 360 Anti-Virus is an anti-virus software that uses multiple scan engines to provide computer virus protection.

• Cloud Storage – The company offers users easily accessible space for file storage and data backup. Users can transmit, access, and manage messages and images via PC software, web pages, and mobile platforms.

• Platform Products – The company offers platforms, such as 360 Safe Browser, 360 Extreme Browsers, 360 Personal Startup Page, and 360 Application Desktop.

• Online Advertising – The company utilizes extensive traffic to support its online advertising services, including online marketing and search referral service. The 360 Browsers, default home pages, and 360 Personal Startup Page contain search boxes tied to search engines for obtaining global data.

• Internet Value-Added Services – The company offers a variety of associated services, including remote technical support, the creation and maintenance of websites, and the operation of web games and applications developed by third parties.

Qihoo 360 Technology continues to broaden and deepen its product and service offerings, leveraging its massive user base to build a comprehensive user platform, offering a growing list of third-party applications, such as e-commerce, travel, SNS, and online video. According to independent statistics, calculated according to the number of users, Qihoo 360 Technology is now one of China’s top three Internet companies.

For more information, visit www.360.cn

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Monday, July 28, 2014

Digital Power Corp. (DPW) Attains $2 Million Defense Export Order

Today, Digital Power reported its wholly owned subsidiary, Digital Power Ltd. has been rewarded a $2 million defense export order from the Republic of Korea. The order calls for providing the Republic of Korea with uninterruptible power systems for installation on Military Afloat Reach and Sustainability tankers being built by Daewoo Shipbuilding and Marine Engineering.

These tankers are being built to deliver logistical support, ammunition and other supplies to Type 45 destroyers while they are at sea. Digital Power already has provided an extensive suite of power conversion and distribution equipment for this destroyer fleet.

Jake Moir, Managing Director of Digital Power Limited, commented, “After nine months of hard work by our Republic of Korea partner, C&A Electric, and us, we are pleased to have secured this important contract. This order will be a major part of our forward order book for the next two years and provides us with a platform to develop additional new products for customers worldwide. Our defense business continues to grow with customers in markets that include Spain, France, Australia, India, and now South Korea.”

Amos Kohn, president and CEO of Digital Power Corporation, commented, “We continue to search for new products and markets and are very pleased to have penetrated this important market segment as part of our ongoing expansion into the international defense industries. The recent award of the Republic of Korea naval defense project to our subsidiary, Digital Power Limited, follows the award of the LVPS project by the Israel Aerospace Industries and demonstrates our expansion of power technologies to the worldwide defense market,” Mr. Kohn continued. “In this increasingly unstable world, we are proud to do our part to support our strategic allies.”

For more information, visit: www.digipwr.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Friday, July 25, 2014

Equisolve to Co-Host ‘Uplisting BootCamp’ August 8, 2014 at NYSE

Equisolve, a leading provider of website development and street communication management to public companies, along with stock transfer agent, Cleartrust, is co-hosting an “Uplisting Bootcamp,” Friday, August 8, 2014 at the New York Stock Exchange, New York, NY. Uplisting Bootcamps provide attendees with valuable information regarding the application process, listing criteria, financial and corporate governance requirements, and ‘a day in the life’ running an exchange-listed company. Featured will be expert panels seating members of the NYSE, Society of Corporate Secretaries and Governance Professionals, Investment Banks, Legal Counsel, D&O Insurance Specialists, and CEOs of recently ‘uplisted’ companies.

Lead sponsors are the New York Stock Exchange and the Society for Corporate Secretaries and Governance Professionals.

Additional information can be found at www.uplistingbootcamp.com. Alternatively, interested attendees can go directly to registration at www.uplistingbootcamp.com/2014/register.

Events will include an expert panel, gourmet meal and networking opportunities. Notably, guests can look forward to NYSE trading floor tours before and after the event.

Equisolve takes the online presence of a public company and turns it into a tool to retain and attract new investors and boost sales. Its proprietary CMS platform uses the corporate website, IR website, newswires, social media, webcasting and teleconferencing and gives Equisolve the ability to market, manage and measure a successful online presence. With servers in over 51 datacenters in 19 countries worldwide, Equisolve’s technical backbone delivers a secure, fast and reliable platform to meet the needs of its customers. If a public company is looking to launch a new web presence, have professionals manage its existing website, or add an Investor Relations page, Equisolve is positioned to assist.

If interested parties are unable to attend the August 8th ‘Uplisting Bootcamp,’ the Los Angeles Athletic Club, Los Angeles, CA, will be the host of the next camp on September 19, 2014.

Other highlights of the August 8th boot camp include the benefits of ‘uplisting’ to a higher exchange, timing and strategies, exchange-listing requirements, understanding the application process and compliance issues and requirements. Confirmed panelists are NYSE, AHT Insurance, law firm EGS, Lippert Heilshorn Investor Relations and Roth Capital Partners. There will be an open forum between 1:30-2:30 highlighted by Q & A and networking.

With a focus on public companies, Equisolve combines design, technology, and expert service to offer the industry’s only self-updating online IR platform. The company has been in the business of helping public companies communicate with investors since 2006.

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

SAGE Therapeutics, Inc. (SAGE) Uses Fast-Tracked SAGE 547 as Springboard in Successful Public Offering

This week, SAGE Therapeutics announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $18.00 per share. Before underwriting discounts, the offering includes the exercise in full by the underwriters of an option to purchase up to 750,000 additional shares of common stock.

Acting as joint book-running managers for the offering were J.P. Morgan Securities LLC and Goldman, Sachs & Co. Leerink Partners LLC acted as lead manager and Canaccord Genuity Inc. acted as co-manager.

The Food and Drug Administration recently granted fast track designation to development program, SAGE-547. The program is an allosteric modulator of GABAA receptors in development for the treatment of adult patients with refractory status epilepticus who previously have not responded to standard procedures. SAGE is currently evaluating SAGE-547 in a Phase 1/2 clinical trial for the treatment of super-refractory status epilepticus (SRSE). Early data shows the first four patients enrolled in the clinical trial met the key effective endpoint, leading to each being successfully weaned off his or her anesthetic agent while SAGE-547 was being administered. There have been no serious drug-related, adverse events in these four patients reported to date.

“The fast track designation for SAGE-547 recognizes the significant unmet need that exists in the treatment of super-refractory status epilepticus,” commented Jeff Jonas, MD, CEO of SAGE Therapeutics. “The receipt of orphan drug designation earlier this year for status epilepticus and the fast track designation are both significant regulatory milestones for SAGE-547, and we will continue to work closely with the FDA to advance our lead compound and the additional programs in our pipeline for the treatment of life-threatening CNS disorders.”

SAGE Therapeutics is a biopharmaceutical company with a focus on developing and marketing novel medicines to treat life-threatening, rare CNS disorders. Its core program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines.

For more information, visit www.sagerx.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Wednesday, July 23, 2014

Skkynet Cloud Systems, Inc. (SKKY) Secure Cloud Service™ to Be Featured at Smart Energy Show in Japan

Today before the opening bell, Skkynet, a global leader in real-time cloud information systems, reported its Secure Cloud Service™ will be featured at the upcoming Smart Energy Show later this month in Japan. There, the Thundercloud™ Alliance will be presenting the service to 10,000-plus embedded system designers and builders. The presentation will include interactive displays to showcase the service’s functionality, real-time performance, and ease-of-use.

Smart Energy Japan is a two-day event in which the public is introduced to different equipment and systems available for controlling energy consumption for consumer, commercial, and industrial user applications. This year’s event will be taking place at the Grand Front Osaka in Osaka, Japan on Tuesday and Wednesday, July 29 and 30, 2014.

The Thundercloud™ Alliance is a group formed in December 2013 by between TOA Musendenki, Nissin Systems, BellChild, NiC, KOBATA Gauge, and Skkynet. It was founded to develop a turnkey, real-time sensor-to-cloud service for the industrial machine-to-machine market.

“This is an excellent opportunity for those at the forefront of embedded systems development in the smart energy sector to see and interact with a fully functional, end-to-end, cloud-based system firsthand,” said Paul Thomas, President of Skkynet. “We are looking forward to some engaging questions and serious conversations.”

The Secure Cloud Service™ is expected to be released on Wednesday, August 13, 2014. It will also be featured at the upcoming M2M Conference on August 12-14 in Las Vegas, Nevada.

For more information, please visit: www.skkynet.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Tuesday, July 22, 2014

VistaGen Therapeutics, Inc. (VSTA) Announces New Agreement with Largest Shareholder

In an 8-K filed with the SEC today, VistaGen Therapeutics announced that Platinum Long Term Growth VII, LLC, the company’s largest investor, has entered into an Amended and Restated Note Conversion Agreement and Warrant Amendment.

According the SEC filing, Platinum has agreed to convert all senior secured convertible promissory notes currently held into unregistered equity securities upon the consummation on or before August 31, 2014, of either a private equity financing resulting in aggregate gross proceeds of at least $36.0 million, or a registered equity financing resulting in gross proceeds of $10.0 million or more. The deal would significantly improve VistaGen’s balance sheet.

Additionally, pursuant to the terms and conditions of the amendment and consummation of a qualified financing on or before August 31, 2014, the exercise price of all warrants issued by VistaGen to Platinum in connection with the notes, and warrants that still may be issued pursuant to the note exchange and purchase agreement dated October 11, 2012, if any, will be fixed at $0.50 per share or the purchase price of common stock sold in the qualified financing, whichever is lower. Finally, the anti-dilutive provisions contained in the warrants, other than typical adjustments for stock splits, combinations and dividends, will be terminated.

Platinum also agreed to terminate the amended and restated security agreement, intellectual property security and stock pledge agreement and negative covenant agreement, each dated October 11, 2012, related to the Notes, and release all of its security interests in the assets of VistaGen and its subsidiaries in connection with the company’s completion of a Qualified Financing and conversion of the Notes.

To read the whole filing, visit www.dtg.fm/vsta-8k-7-22-14

For more information on VistaGen, visit www.vistagen.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Friday, July 18, 2014

What You Need to Know about Canada’s New Anti-Spamming Legislation

In an effort to beef-up the Canadian online marketplace, Canada recently passed new anti-spam legislation (CASL). Changes in Canadian e-communication laws were unfurled July 1, 2014, and whether you’re based in Canada, the United States or Dubai, if you haven’t noticed the change just yet, you may soon feel the ripples in the way you receive and share email communication with recipients up north.

In short, the CASL runs counter to the traditional opt-out or unsubscribe models to stop receiving unwanted email, and instead includes a strict opt-in model for B2B email messaging whereby recipients must proactively agree to receive email from businesses.

Per the legislation, if you are sending a commercial electronic message (CEM) to a Canadian recipient, you need to comply with three requirements: obtain oral or written consent; provide identification information; and provide an unsubscribe mechanism.

CEMs are emails inclusive of the promotion of a product or service that encourages the recipient to purchase the item or services. This includes the promotion of people, public image, goods, land or even a business, investment or gaming opportunity. There is an exemption for persons sending CEMs to other persons within their organization, as well as for communication between two organizations that have a business relationship.

Think twice before you consider toeing the line with CASL. Committing a violation under CASL can carry a hefty fine – up to $1 million for an individual and up to $10 million for a business.

For more information visit www.crtc.gc.ca

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Wednesday, July 16, 2014

Continental Stock Transfer & Trust Company Answers Your Questions

Continental Stock Transfer & Trust Company’s commitment to accessibility and service, focused on small to medium emerging and growth companies, has always been a cornerstone of their stated mission, differentiating them in the marketplace. They go out of their way to make it easy for clients and shareholders to get answers, and they know the most common questions, some of which are shown below.

• What are the best ways for shareholders to contact Continental Stock Transfer & Trust Company?

• How should a shareholder change their mailing address?

• How can you replace a lost stock certificate?

• How can shares be sold?

• How can you tell if an old security still has value?

• How can you replace a dividend check?

• Why was tax withheld from a dividend payment?

• How to obtain a copy or a corrected Form 1099?

• How to exchange certificates for DRS shares?

• What’s the best way to mail shares for transfer to Continental?

• How to transfer (change ownership) of shares?

• What are the most common types of security registrations?

• How are shares transferred out of a decedent’s name?

• How is a deceased joint tenant removed as a registered holder?

• What is a beneficial shareholder, versus registered shareholder?

• What is a guarantor?

• What is a Medallion Guarantee?

For the answers to these and other questions, visit www.ContinentalStock.com/faqs

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Windstream Technologies (WSTI) Plays Key Role in World’s Largest Hybrid Renewable Energy Project

Windstream Technologies is playing a pivotal role in the world’s largest hybrid renewable energy project. Commissioned on the roof of law firm Myers, Fletcher and Gordon (MFG) in Kingston, Jamaica, and being referred to as a landmark urban installation, the project consists of 50 WindStream SolarMill® units used to capture available wind and solar resources.

The installation is expected to generate over 106,000 kWh of renewable energy each year, (25kW of wind and 55kW of solar) with a return on investment of less than four years. Over the course of an approximate 25-year life span, the energy cost savings are expected to exceed $2 million. WindStream was awarded the project due to its ability to maximize energy production and return on investment – all in an area consisting of limited roof space.

“We have been at the forefront of the Jamaican legal landscape for 70 years and we are pleased to be continuing that trend by leading inJamaican sustainability and renewable energy,” said Donovan Cunningham, COO of Myers Fletcher & Gordon. “This was a bold undertaking and we expect to reap rich rewards through our partnership with WindStream.”

The MFG SolarMill installation is a component of an overall effort by Jamaica Public Service (JPS) to provide greater access to renewable energy solutions in a country where the cost of energy is over three times the US average. JPS and WindStream also worked with Eaton Houghton of Caribbean ESCO as the Caribbean’s lead energy efficiency auditor for the project.

“We are proud to be working with JPS, which is distributing our products within Jamaica and throughout the Caribbean,” said Travis Campbell, COO of WindStream Technologies. “This SolarMill installation is an excellent model for other businesses to follow. If you are interested in energy efficiency and saving money, SolarMills are a simple, cost-effective solution.”

WindStream Technologies, founded in 2008, is a public company headquartered in North Vernon, Indiana. WSTI’s mission is to create low-cost hybrid, renewable energy solutions for on and off-grid, urban and suburban environments. Made in the USA, its patented SolarMill® technology is a distributed energy solution that produces constant renewable energy for customers. The company’s products are sold around the world.

For more information on the company, visit www.windstream-inc.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Tuesday, July 15, 2014

Millions in Grant Funding Provide Foundation of Opportunity for VistaGen Therapeutics, Inc. (VSTA)

The National Institute of Health aims to supports biomedical science and behavioral research through the pursuit of knowledge of the biology and behavior of living systems and to then apply that knowledge to “extend healthy life and reduce the burdens of illness and disability.” NIH’s own role in this mission includes the provision of funding grants and/or cooperative agreements. To ensure that funds are allocated to organizations aligned with this goal, NIH first determines whether or not the applying company’s project will yield a “sustained, powerful influence on the research field(s) involved.”

Obtaining a grant is much more than a simple petition and business plan. In order for a company to receive a grant from NIH, an applying company’s project must undergo peer review and demonstrate, in addition to other considerations, the following five criteria:

• Significance – address an important problem or critical barrier to progress in the field; Investigators – doctors, collaborators and other researchers must be well-suited, experienced and trained for the project;

• Innovation – the application must challenge and seek to shift current research or clinical practice by utilizing novel concepts, approaches, instrumentation or intervention;

• Approach – appropriately strategized to accomplish the specific aim of the project; and

• Environment – will scientific environment in which the work will be conducted contribute to the probability of success?

The rewards of meeting these criteria are often invaluable. Case in point: VistaGen, Inc., a San Francisco-based stem cell company focused on drug rescue and regenerative medicine backed by a team of stem cell research and development teams and collaborators that for 15 years have focused on controlling the differentiation of pluripotent stem cells to produce multiple types of mature, functional, adult human cells for drug rescue applications.

Since its inception in 1998, the company has received a total of $8.8 million in grant funding from the NIH for phase 1 clinical development of its AV-101 lead small molecule drug candidate.

This funding enabled the company to complete phase 1 development of AV-101, an orally available small molecule prodrug candidate designed to address needs in the multi-billion dollar neurological disease disorders market, such as neuropathic pain, epilepsy and depression. VistaGen has submitted an AV-101 IND application with the U.S. FDA to cover clinical development for neuropathic pain, though the company believes that completed phase 1 AV-101 safety studies will also support development of AV-101 for multiple indications, including epilepsy and depression.

VistaGen’s plan, contingent upon completion of this offering, is to pursue potential opportunities for further development and commercialization of AV-101 on a stand-alone or corporate partnership basis. If successful, the company says it intends to use the net proceeds from such an arrangement to expand its drug rescue and regenerative medicine programs, which are based on its stem cell technology platform, Human Clinical Trials in a Test Tube™.

Receiving NIH funding marked a pivotal moment in VistaGen’s history, providing the company with a monetary avenue to pursue its broader mission to commercialize therapeutically and commercially promising regenerative medicine programs.

For more information, visit www.VistaGen.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

TraderPower – Empowering Investors to Discover Exceptional Opportunities

TraderPower was established to empower investors with all the resources they need to make profitable trading decisions. Using the vast resources on the TraderPower website, the investment community can discover undervalued small-cap companies, learn how to properly analyze investment opportunities, and utilize free research tools for in-depth evaluation.

TraderPower’s #1 focus is on connecting investors with undervalued small-cap companies that are trading far below their true worth. With an estimated 15,000 publicly traded companies, it’s no surprise that these stocks exist. Of course once these neglected equities begin to get noticed, the climb to their fair valuation can be exceptionally profitable in a very short time.

Want to learn more? Visit www.TraderPower.com and discover your next profitable investment

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Thursday, July 10, 2014

Stellar Biotechnologies, Inc. (SBOTF) Reports Q3 2014 Financial Results and Corporate Update

Stellar Biotechnologies, a leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), today reported its financial results for the third quarter and nine months ended May 31, 2014. It also provided a few operational highlights from that time frame as well.

Financial Results:

• Cash Position: Cash and cash equivalents as of May 31, 2014 were $14.8 million, compared to $ 7.9 million at year-end August 31, 2013. The Company believes current cash will be sufficient to meet estimated working capital requirements and fund planned program development through 2015. During the nine months ended May 31, 2014, the Company received $7 million gross proceeds under private placements (with $5 million of the September 2013 private placement subscribed and received prior to August 31, 2013) and $4.2 million gross proceeds from the exercise of warrants and options.

• Shareholder Statistics: As of May 31, 2014, Stellar had shareholders equity of $11.1 million and approximately 78 million shares outstanding.

• Revenues: Revenues were $102,581 in the third quarter and $252,848 for the nine months ended May 31, 2014 compared to $73,214 and $250,422 in the comparable periods in 2013. Stellar completed the NSF Phase IIB grant during the first quarter of 2014 and generated additional contract and commercial sales revenue during the second and third quarter.

• R&D Expenses: Research and development expenses were $462,129 in the third quarter of 2014 and $1.37 million in the nine months ended May 31, 2014, compared to $178,202 and $684,662 in the comparable periods in 2013. The increase in R&D expense was largely due to an increase in method development activities for vaccine manufacturing during the period related to the C. diff active immunotherapy research program.

• Other Operating Expenses: Other operating expenses totaled $864,485 in the third quarter of 2014 and $2.98 million in the nine months ended May 31, 2014, compared to $582,152 and $1.74 million in the comparable periods in 2013. The increase was primarily attributable to a higher level of activity, addition of key personnel, vesting and timing of stock options, and discontinuation of the temporary voluntary salary reduction that were initiated in the prior comparison period.

• Net Income (Loss): Net income was $1.81 million for the third quarter of 2014 and a net loss of $3.8 million for the nine months ended May 31, 2014, compared to net loss of $1.17 million and $5.58 million for the comparable periods in 2013. The decrease of $2.98 million in net loss for the third quarter of 2014, and cumulative decrease of $1.78 million net loss for the nine months ended May 31, 2014 were substantially affected by fluctuations in noncash change in fair value of warrant liability. During the three months ended May 31, 2014, there was a gain on fair value of warrant liability of $3.02 million (2013 – loss of $353,119) for a net fluctuation of $3.38 million additional gain than the prior period. The gains and losses in these periods are a reflection of the Company’s share price fluctuations with increases in share prices causing greater warrant liability and a loss on fair value of warrant liability, while decreases in share prices cause a gain on fair value of warrant liability. Changes in fair value of warrant liability have no impact on cash flow. If the warrants are exercised, the warrant liability is reclassified to share capital. If the warrants expire, the decrease in warrant liability offsets the changes in fair value.

Operational Updates:

• Collaborations and KLH Supply Agreements: Stellar KLH(TM) is currently used by the Company’s biopharma partners as the carrier in certain new immunotherapies in clinical development for cancer, autoimmune disease, and inflammatory disease. Those programs continued to progress in 2014 and Stellar met all contract requirements related to supply and/or development of KLH protein for those product candidates. In addition, Stellar continues to strengthen its collaboration expansion with biopharma companies as their immunotherapy programs advance in the clinic to later stages of development and potential regulatory submissions. These strategic collaborations represent multiple commercial pathways for Stellar including future growth of core business sales and close involvement in the development of new KLH-based immunotherapies.

• C. diff Active Immunotherapy Program: During the first half of 2014, Stellar successfully advanced its C. diff active immunotherapy program in key preclinical areas including early process development and the scale-up and transfer of essential manufacturing methods to a contract manufacturing organization (CMO). The goal of this stage of product development is to establish scalable processes necessary to support GMP production of a PS-KLH conjugate vaccine candidate. In the second half of 2014, the Company will focus on completing certain IND-enabling milestones such as identification of appropriate PS-KLH formulation, demonstration of dose ranging and safety, intermediary scale-up and manufacturing of test material in preparation for clinical production.

“This has been an important strategic year for Stellar and we are pleased to report positive momentum in key facets of our KLH business,” said Frank Oakes, President and CEO of Stellar Biotechnologies. “Our corporate collaborations, where Stellar KLH is used as the critical carrier molecule in new therapeutic vaccines, are strong and poised for clinical advancement. And we are on track in the preclinical development of our own C. diff immunotherapy program. We are confident that these initiatives will enhance valuation for our shareholders as well as expand Stellar’s long-term commercial potential.”

For more information about Stellar Biotechnologies, please visit: www.stellarbiotech.com

Breitling Energy Corp. (BECC) Helps ‘Tee Up’ America’s Solution to Dependence on Imported Oil

Is fracking technology, the hydraulic process that enables the extraction of domestic oil and natural gas from shale-rock deposits, the magic bullet? The one that will finally slay the Middle East’s oilfield mega-gorilla who’s been holding the U.S. and much of the rest of the energy-thirsty western world hostage since the 1970s?

To many oil industry engineers, economists, financial analysts and executives, like Breitling Energy Corporation’s CEO, president and chairman Chris Faulkner, the question isn’t really about whether the technology will achieve the desired end result, but when it will do so. And the answer most experts tracking the industry believe is “right about now.”

According to the International Energy Agency, the United States — thanks in large part to advances in fracking efficiency pioneered by Breitling and others — will, by the end of 2014, surpass Russia and Saudi Arabia to become the world’s top oil producer for the first time in almost 50 years.

Though some oil company veterans have been a bit slow to realize the major implications of North Dakota’s Bakken Field, Montana’s Three Forks reserves, and other oil-and-gas-bearing shale deposits, Breitling’s Faulkner is one Texas oilman who not only saw the handwriting on the wall early on, but helped put it there.

Faulkner, author of the recently published book The Fracking Truth, executive producer of “Breaking Free,” a film about the shale-oil revolution, and winner of numerous “industry leader of the year,” “oil executive of the year,” and “best North American [energy company] operator of the year” awards, notes that “fracking has teed up America to solve this problem (of dependence on foreign sources to fuel its economy) with less risk and at greater gain than any other nation on earth.”

Headquartered in Dallas, Texas, Breitling has planted its drilling roots deeply in both old school and new age methods of finding oil and natural-gas deposits and wrestling them from their ancient hiding places. Their avowedly “lower-risk acquisition, exploration and development” operations are focused on preliminary and secondary oil and natural gas recovery in both traditional U.S. “oil play” areas and “shale play” (also known as “unconventional liquid play” to industry insiders) sites such as the Marcellus range in the Appalachians, Eagle Ford, Texas, Three Forks in Montana, and, of course, the Bakken fields in North Dakota.

By using state-of-the-art technologies such as 3D seismic modeling and CO2 tertiary-recovery technology, Breitling has frequently been able to reduce costs and improve yields to the point where even abandoned drilling fields previously believed unworkable are now yielding significant bottom-line returns.

“Our operating areas are characterized by long-lived natural gas and oil reserves and established production capabilities, with abundant growth opportunities. In each of the company’s operating areas, our deep backlog of drilling locations enables us to establish substantial economies of scale in drilling and production operations for more effective drilling and reservoir management practices,” Faulkner says.

Winner of the IAIR 2014 “Best Company Award for Leadership in Oil & Gas Extraction in the USA” and the 2013 “Aggreko Award for Excellence in Environmental Stewardship” in the Gulf Coast Region, Breitling’s culture is based on the concept that energy production, economic growth and development, and a clean and healthy environment are mutually inclusive rather than mutually exclusive.

“Being honored by the IAIR, whose panel of judges includes scientists and experts in law and finance from more than 120 nations, highlights an incredible decade of achievements and successes since Breitling’s founding in 2004,” states Faulkner.

“Between the release of the documentary ‘Gasland’ and the Deepwater Horizon disaster, I was stunned at how poorly the industry responded,” Faulkner said in a recent issue of “Energy Executive” magazine. “We still have a long way to go in trying to tell the full story. What I’ve learned through experience is that we have to do a much better job of getting our story out there, with full transparency and a willingness to face the tough questions.”

Among other core beliefs rooted in transparency toward shareholders, the public, and regulators, Faulkner believes the best way to handle tough questions is to meet them with responsive solutions. Which is one reason why he founded the Breitling Oil and Gas EnviroFrac™ research program in early 2010.

EnviroFrac™ scientists are charged with evaluating the environmental impact of additives typically used in hydraulic fracking operations and developing greener alternatives for those additives which pose either current or potential ecological hazards.

“EnviroFrac™ is a decisive move toward a greener fluid system,” Faulkner notes. “By reviewing all of the ingredients used in each frac, the program identifies chemicals that can be removed and tests alternatives for remaining additives. We are very proud that we have, to date, eliminated 25 percent of the additives that used to be key components in our shale operations. Our eventual goal is to replace any that pose even a slight threat to the people who work at or live adjacent to our project sites.”

For more information, visit www.breitlingenergy.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html